1. LRRK2 and the Endolysosomal System in Parkinson’s Disease
- Author
-
Madalynn L Erb and Darren J. Moore
- Subjects
0301 basic medicine ,Cell type ,Leucine-rich repeat kinase 2 ,Review ,Endosomes ,Biology ,Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 ,Endocytosis ,03 medical and health sciences ,Cellular and Molecular Neuroscience ,VPS35 ,lysosomes ,0302 clinical medicine ,Animals ,Humans ,Kinase activity ,Synaptic vesicle endocytosis ,Kinase ,trans-Golgi network ,Autophagy ,Parkinson Disease ,LRRK2 ,nervous system diseases ,Cell biology ,030104 developmental biology ,Parkinson’s disease ,Neurology (clinical) ,vesicular trafficking ,030217 neurology & neurosurgery ,Signal Transduction - Abstract
Mutations in leucine-rich repeat kinase 2 (LRRK2) cause autosomal dominant familial Parkinson’s disease (PD), with pathogenic mutations enhancing LRRK2 kinase activity. There is a growing body of evidence indicating that LRRK2 contributes to neuronal damage and pathology both in familial and sporadic PD, making it of particular interest for understanding the molecular pathways that underlie PD. Although LRRK2 has been extensively studied to date, our understanding of the seemingly diverse functions of LRRK2 throughout the cell remains incomplete. In this review, we discuss the functions of LRRK2 within the endolysosomal pathway. Endocytosis, vesicle trafficking pathways, and lysosomal degradation are commonly disrupted in many neurodegenerative diseases, including PD. Additionally, many PD-linked gene products function in these intersecting pathways, suggesting an important role for the endolysosomal system in maintaining protein homeostasis and neuronal health in PD. LRRK2 activity can regulate synaptic vesicle endocytosis, lysosomal function, Golgi network maintenance and sorting, vesicular trafficking and autophagy, with alterations in LRRK2 kinase activity serving to disrupt or regulate these pathways depending on the distinct cell type or model system. LRRK2 is critically regulated by at least two proteins in the endolysosomal pathway, Rab29 and VPS35, which may serve as master regulators of LRRK2 kinase activity. Investigating the function and regulation of LRRK2 in the endolysosomal pathway in diverse PD models, especially in vivo models, will provide critical insight into the cellular and molecular pathophysiological mechanisms driving PD and whether LRRK2 represents a viable drug target for disease-modification in familial and sporadic PD.
- Published
- 2020